SR Pharma plc Announces Start of Phase I trial with Novel RNAi Therapeutic RTP-801i in Age- related Macular Degeneration (AMD)
07-Feb-2007 -
SR Pharma plc announced that Quark Biotech Inc. has started a Phase I clinical trial with RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma plc. RTP-801i is based on Atugen's proprietary siRNA (AtuRNAi) technology and modifies the ...
clinical trials
diseases
Expression
+2